



Advance Program for the AHNS 2024 Meeting at COSM Catalyzing Practice Change Through Translational Clinical Research

Registration Now Open at <https://cosm.md/>

AHNS Accreditation Statement for AHNS 2024

The American Head & Neck Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Head & Neck Society designates this live activity for a maximum of 13.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABOHNS Continuous Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn their required annual part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery's Continuing Certification program (formerly known as MOC). It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of recognizing participation.

ABS Continuous Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME requirement(s) of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Program Chair: Patrick Ha, MD, FACS, Program Co-Chairs: Nicole Schmitt, MD and Sidharth Puram, MD, PhD

AGENDA:

***More Information to be Announced. Tentative Schedule – Subject to Change*

Tuesday, May 14, 2024 (Pre-Meeting Courses)

Time	Title	Location
8:30am-5:05pm	2024 AHNS Innovation and Entrepreneurial Symposium (non-CME) Course Director: <i>Jose P. Zevallos, MD, MPH</i> Course Co-Director: <i>Baran Sumer, MD</i>	Grand Ballroom K
	<p>This symposium will be an introductory, all-day course designed for surgeons and academic physicians. It offers insights into entrepreneurship, covering key aspects such as intellectual property protection, capital raising, balancing clinical responsibilities, navigating technology transfer offices, patenting, commercialization, manufacturing, regulatory compliance, and conflict of interest management.</p> <p>Welcome and Introduction – <i>Jose P. Zevallos, MD, MPH</i> The Creative Process for Surgeons – <i>Carl Snyderman, MD</i> Now That I have a Good Idea, How Do I Develop It? Therapeutics and Medical Devices – <i>Peter Santa Maria, MD, PhD</i> Protecting Your Idea: The Disclosure and Intellectual Property Process – <i>Tom Meyers</i> Leveraging University Resources Panel - Moderator: <i>Nishant Agrawal, MD, FACS</i> Panelists: <i>Melissa Byrn, Barbara Flynn, MD, David Johnson, PhD, Jennifer Ponting, JD, Robert Rosa, MD</i> Surgeons as Entrepreneurs Panel: Conceptualization of Your Idea and Launching Your Start-Up Moderator: <i>Jose P. Zevallos, MD, MPH</i> Panelists: <i>Nishant Agrawal, MD, FACS, Alex Langerman, MD, SM, FAC, Peter Santa Maria, MD, PhD, Carl Snyderman, MD,</i></p>	
	Networking Lunch	
	Keynote Lecture in Entrepreneurship and Innovation, “Commercializing Your Discoveries: An Entrepreneur’s Perspective” – Stan Lapidus	
	<p>The inaugural AHNS Lecturer in Entrepreneurship and Innovation will be Stan Lapidus. Stan is a serial inventor and entrepreneur. He is the founder of two multibillion-dollar diagnostics companies, Cytoc and Exact Sciences. Stan is the inventor of Cytoc's ThinPrep pap test used worldwide for cervical cancer screening. He is the co-inventor of Exact's Cologuard test for early detection of colorectal cancer. Stan serves as a director of seven companies and is chair of three of them. Stan has held faculty appointments at MIT and Tufts Medical School. He holds 37 US patents and is an elected fellow of the American Institute of Medical and Biological Engineering. He is also a co-founder of Droplet Biosciences.</p> <p>Creating Your Pitch Deck – <i>Theresa Tribble, MBA</i> How to Raise Capital, from Seed to Series A and Beyond – <i>Jennifer Fried, MBA, Alex Langerman, MD, SM, FACS</i> Venture Capital Panel: Working with Surgeon Founders - Moderator: <i>Baran Sumer, MD</i> Panelists: <i>Clay Heighten, MD, Tony Natale, MD</i> “Entrepreneurship While Keeping Your Day Job” Panel - Moderator: <i>Alex Langerman, MD, SM, FACS</i> Panelists: <i>Chris Holsinger, MD, Baran Sumer, MD, Jose P. Zevallos, MD, MPH</i> Closing Remarks - <i>Jose P. Zevallos, MD, MPH</i></p>	

8:00am-12:00pm	Thyroid, Parathyroid, and Neck Ultrasound Course Didactic Session	Grand Ballroom L
12:00pm-12:15pm	Lunch	Grand Ballroom MN
12:15 pm-5:00pm	Thyroid, Parathyroid, and Neck Ultrasound Course Hands On Session	Grand Ballroom MN

The objective of this course is to introduce the practicing surgeon to office-based ultrasound examination of the thyroid and parathyroid glands and related pathology. The distinction of normal from malignant lymphadenopathy is emphasized with a demonstration of the comprehensive examination of lymph node basins in cervical zones I-VI. The process of ultrasound guided FNA of thyroid nodules and enlarged lymph nodes is demonstrated in didactic lecture format. In addition skill sessions allow the surgeon to learn varied techniques of FNA of lesions in phantom models.

The use of patient volunteers with thyroid and parathyroid pathology and lymphadenopathy will allow supervised hands-on experience with transverse and longitudinal ultrasound methods. Participants will be instructed in the practical details and hurdles in developing office-based ultrasound.

1:00pm-5:00pm	Head & Neck Microvascular Reconstruction Workshop for Residents/Fellows (non-CME) Course Chairs: <i>Steve Chinn, MD, MPH, BS and Jamie Ku, MD, BS</i>	Grand Ballroom L
<p>This workshop will highlight key harvest techniques of both common and uncommon reconstructive procedures utilizing multimedia presentations, including videos and images. In the second part of the workshop, a group of experts will provide insights and pearls of wisdom as they work through defect-oriented cases of to provide solutions to some of the most challenging head and neck reconstructive defects.</p> <p>At the conclusion of this session participants will be able to:</p> <ul style="list-style-type: none"> Identify key harvest techniques of both common and uncommon head and neck reconstructive procedures. Understand the various reconstructive options to some of the most challenging head and neck cancer defects. 		

Wednesday, May 15, 2024

Time	Title	Location
7:00am-5:00pm	Centurion Lounge	Skyway 260
7:00am-8:00am	New Member Induction Ceremony	Grand Ballroom EF
8:00am-8:05am	Introduction <i>Robert Ferris, MD, PhD</i>	Grand Ballroom EF
8:05am-8:40am	Distinguished Keynote Lecture <i>Norman Wolmark, MD, FACS, FRCSC</i>	
8:40am-8:45am	Introduction <i>Bill Lydiatt, MD</i>	
8:45am-9:45am	Presidential Address <i>Robert Ferris, MD, PhD</i>	
9:45am-10:15am Break with Exhibitors		
10:15am-11:15am	John Conley Lecture Keynote Speaker: <i>Marty Makary, MD</i>	Grand Ballroom EF
Blind Spots: The Business of Medicine, The Appropriateness of Care, and Unexplored Areas of Research		

Time	Title	Location	Time	Title	Location
11:15am-12:00pm	Scientific Session 1: Reconstruction/ QOL	Grand Ballroom EF	11:15am-12:00pm	Panel Discussion: Neoadjuvant Immunotherapy: Standard of Care and Ongoing Trials	Grand Ballroom IJ
	<ol style="list-style-type: none"> 1. Impact of baseline emotional distress on long-term quality of life in head and neck cancer patients – <i>Kimberly Oslin, MD</i> 2. Trajectories of Neck Disability and Dysphagia Symptoms in Survivors of Head and Neck Cancer – <i>Marci L. Nilsen, PhD, RN, CHPN, FAAN</i> 3. The 5 item modified frailty index predicts postoperative morbidity, not survival following laryngectomy – <i>Eoin F. Cleere, MB, BCh, MCh</i> 4. Impact of Frailty on Treatment Selection in Locally Advanced Laryngeal Squamous Cell Carcinoma – <i>James R. Xu, BS</i> 5. Hardware Exposure Following Mandibular Reconstruction Using Osteocutaneous versus Soft Tissue Microvascular Free Tissue Transfer – <i>Hasan Abdulkabi, BA</i> 6. Tranexamic Acid in Head and Neck Microvascular Free Flap Reconstruction – <i>Micah K. Harris, MD</i> 			<p>Moderator: <i>Kelly Malloy, MD</i></p> <p>This session will provide a review of the current science of neoadjuvant immunotherapy in head and neck oncology, from its use in melanoma and cutaneous squamous cell carcinoma to newer investigations for mucosal malignancies. We will also have an opportunity to consider fresh science in this arena via the presentation of a relevant abstract during the session.</p> <p>At the conclusion of this session participants will be able to:</p> <ul style="list-style-type: none"> ● Apply standard of care neoadjuvant immunotherapy options in appropriate melanoma patients. ● Use appropriate neoadjuvant immunotherapy for cutaneous SCC of the head and neck. ● Identify clinical trial opportunities for neoadjuvant immunotherapy in mucosal head and neck cancer patients. <ol style="list-style-type: none"> 1. Response-Adapted Oncologic Surgery for Cutaneous Squamous Cell Carcinoma: Personalized Approach in the Immunotherapy Era – <i>Shorook Naara, MD, PhD</i> 2. Standard of Care and New Horizons in Neoadjuvant Immunotherapy for Melanoma – <i>Jeffrey Sosman, MD</i> 3. Emerging Role of Neoadjuvant Immunotherapy for Cutaneous Squamous Cell Carcinoma – <i>Neil Gross, MD, FACS</i> 4. Advances in Neoadjuvant Immunotherapy for HNSCC – <i>Ravindra Uppaluri, MD, PhD</i> 	

12:00pm-1:00pm Lunch with Exhibitors

1:00pm-2:00pm	Patient Care Debates Part I: TORS vs XRT for Stage I-II HPV+ Oropharynx Cancer	Grand Ballroom EF	1:00pm-2:00pm	Panel: Disparities in Head and Neck Cancer Care: Are We Making Progress? What Are The Opportunities?	Grand Ballroom IJ
	Moderator: <i>Chris Holsinger, MD</i>			Moderator: <i>Caitlin McMullen, MD, BS</i>	
	<p>Despite prospective studies to de-escalate treatment for HPV+ oropharynx cancer, RTOG1016 and HNO05, for now, definitive treatment for most patients appears to be 70Gy XRT + cisplatin. However, frontline surgery with 50Gy post-operative RT has been shown as a feasible treatment approach for selected patients. However, there is considerable variation in practice across the US. In this session, two leaders in TORS and de-escalation approaches using XRT present their recommendation for which patients are ideally suited for treatment de-escalation.</p> <p>At the conclusion of this session participants will be able to:</p> <ul style="list-style-type: none"> ● Integrate recent prospective clinical trials data with expert opinion to optimize treatment selection for patients with HPV+ OPC. ● Identify which patients are ideally suited for frontline surgery using TORS + neck to optimize function outcome and reduce the extent of adjuvant therapy. ● Identify which patients are eligible for XRT treatment de-escalation using tumor hypoxia fMISO PET. <ol style="list-style-type: none"> 1. The Controversy, Conundrum, and a Poll – <i>Chris Holsinger, MD</i> 2. TORS is the Only Evidence-Based Approach for De-escalation – <i>Greg Weinstein, MD</i> 			<p>During this session, our speakers will review the current state of disparities in head and neck cancer care. Novel strategies to increase access to high quality care and clinical trials will be presented.</p> <p>At the conclusion of this session participants will be able to:</p> <ul style="list-style-type: none"> ● Articulate the current state of disparities in head and neck cancer care and the importance of addressing barriers to high quality care. ● Implement strategies during clinical trial design to encourage the enrollment of underrepresented patient populations. ● Apply new technology to identify disparities and develop strategies that can address critical obstacles. <ol style="list-style-type: none"> 1. The Role of AI in Disparities and Solutions – <i>Vasu Divi, MD</i> 2. Promoting Diversity in Clinical Trial Participation – Access and Telehealth - <i>Leila Mady, MD, PhD, MPH</i> 3. Engagement and Care of Patients with Poor Access – <i>Gina Jefferson, MD</i> 4. Assessment of Social Vulnerability in Laryngeal Cancer Prognosis and Treatment in the United States – <i>Camaren M Cuenca, BS</i> 5. Social Determinants of Health in Donor Site Morbidity in Head and Neck Cancer Reconstructive Limbs: Anterolateral Thigh and Fibula Free Tissue Transfers – <i>Emma Elbert, BS</i> 	

3. Using Hypoxia to De-escalate Radiation – *Nancy Lee, MD*
4. Rebuttal and Reply – *Greg Weinstein, MD*
5. Rebuttal and Reply – *Nancy Lee, MD*
6. Summary – *Chris Holsinger, MD*

Patient Care Debates Part II: Are the Days of Targeted Therapy Over or are the Brightest Days Ahead?

Moderator: *Sidharth Puram, MD, PhD*

This debate will explore the emergence of biologic-based therapies for head and neck cancer, specifically focusing on the advantages, challenges, and prospects related to targeted therapy. Our debaters will consider true patient-specific, targeted molecular agents vs broad scale, 'off the shelf,' patient agnostic approaches such as immunotherapy.

At the conclusion of this session participants will be able to:

- Describe the emerging biologic therapies in head and neck cancer.
- Compare the advantages and disadvantages of various targeted agents compared to other emerging therapies (e.g. immunotherapy).
- Appraise the current trial data in this area and integrate these data into ongoing discussions of future therapies.

1. Introduction – *Sidharth Puram, MD, PhD*
2. Pro-targeted Therapy Position – *Luc Morris, MD, MSc*
3. Pro-off the Shelf Position – *Clint Allen, MD, BS*
4. Pro-targeted Therapy Rebuttal– *Luc Morris, MD, MSc*
5. Pro-off the Shelf Rebuttal– *Clint Allen, MD, BS*
6. Conclusion – *Sidharth Puram, MD, PhD*

2:00pm-2:45pm

Grand Ballroom EF

Panel Discussion: Survivorship 2024

Moderator: *Barry Wenig, MD*

With improvement in care, there are ever growing numbers of Head and Neck cancer survivors. This session will detail the complexities of cancer survivorship, changing symptoms over time, and explore challenges in optimizing best care for this population.

At the conclusion of this session participants will be able to:

- Recognize various Quality of Life (QoL) management challenges such as lymphedema, xerostomia, and osteoradionecrosis (ORN).
- Identify the timing and profile of late effects of radiation on swallowing and function.
- Integrate complementary and support services to address psychological needs of survivors.

1. Introduction – *Barry Wenig, MD*
2. Managing QoL Challenges Part 1 – *Jeffrey Liu, MD*
3. Managing QoL Challenges Part 2 – *Theresa Guo, MD*
4. Late Effects of Radiation Therapy – *Rosemary Martino, PhD*
5. QoL Psychological Effects - *Trevor Hackman, MD*

2:00pm-2:45pm

Grand Ballroom IJ

Panel Discussion: Challenges in Salivary Tumors: A Case-Based Discussion

Moderator: *Jessie Maxwell, MD, MPH*

Panelists: *Kiran Kakarala, MD, William Ryan, MD, Shaum Sridharan, MD, Mirabelle Sajisevi, MD*

We will use a case-based format to discuss challenges in the management of salivary gland neoplasms. Topics and controversies to be presented include management of the facial nerve, the role of neck dissection, indications for adjuvant radiation, and soft tissue reconstruction for low- and high-grade salivary gland malignancies.

At the conclusion of this session participants will be able to:

- Articulate the indications for facial nerve sacrifice and various methods for facial nerve reconstruction or facial re-animation.
- Develop a treatment paradigm for soft tissue reconstruction of parotid gland defects.
- Convey the role of adjuvant radiation for close or positive margins in low- and intermediate-grade salivary gland carcinoma.

1. Parotid Acinic Cell Carcinoma
2. Carcinoma Ex Pleomorphic Adenoma
3. Salivary Gland Neoplasm of Uncertain Malignant Potential (SUMP)

2:45pm-3:15pm Break with Exhibitors

3:15pm-4:00pm

Grand Ballroom EF

Scientific Session 2: Cancer Biology/ TME

1. Circulating Tumor DNA Kinetics Following Induction Chemotherapy Predicts Response in HPV+ Oropharyngeal Squamous Cell Carcinoma – *Zachary M. Huttinger, MD, PhD*
2. Cancer stem cells resist targeting by tumor infiltrating lymphocytes in a three-dimensional in vitro model – *Colleen Hochfelder, MD*
3. Prognostic utility of a gene expression profile that quantifies anti-tumor immunity in HPV+ OPSCC – *Dominick Rich, BS*
4. Characterization of the Primary Tumor-Sentinel Node ImmunoMigratome Demonstrates a Key Role for Dendritic Cell Trafficking in the Successful Response to Immunoradiotherapy – *Robert Saddawi-Konefka, MD, PhD*
5. Durable Antitumor Immunity After Successful Primary Tumor Responses to IO Therapy is Conferred by CD8 Tex-stem Cells Residing Within Regional Lymphatics – *Robert Saddawi-Konefka, MD, PhD*
6. Decreased T-cell repertoire and lower density of antigen-presenting cells in the tumor microenvironment of immunosuppressed patients with non-melanoma skin cancer suggest impaired innate immunity is a key driver of immunosuppression – *Jennifer L. Anderson, MD, PhD*

3:15pm-4:00pm

Grand Ballroom IJ

Panel Discussion: Translational Advances in Thyroid Cancer

Moderator: *Alessa Colaianni, MD*

We will use a case-based presentation to discuss translational advances in thyroid cancer, including the use of molecular markers, guidance in patient selection for surgery or conservative surveillance, and use of targeted therapy in advanced disease.

At the conclusion of this session participants will be able to:

- Describe molecular markers and biological correlatives relating to the management of thyroid cancer.
- Describe current trends in the rationale for surgical selection versus conservative surveillance in the management of thyroid cancer.
- Describe recent advances in targeted therapy for advanced thyroid cancer and demonstrate how these therapies interplay with surgery in the multidisciplinary management of advanced thyroid cancer.

1. Introduction and Case Presentation – *Alessa Colaianni, MD*
2. Molecular Markers and Biological Correlatives in Thyroid Cancer – *Elizabeth Cottrill, MD*
3. Surgical Selection vs Conservative Surveillance of Thyroid Cancer – *Merry Sebelik, MD*
4. Integration of Targeted Therapy and Surgery in Advanced Thyroid Cancer Clinical Trials – *Mark Zafereo, MD*
5. Surgical and Oncologic Outcomes of Conversion Surgery vs Immediate Surgery for Patients with Low-Risk Papillary Thyroid Carcinoma – *Helena Levyn, MD*
6. Q&A

4:00pm-5:00pm

Grand Ballroom EF

Women In Head and Neck Surgery Panel- Building Impactful Programs

Moderator: *Shirley Su, MBBS*

Building a coherent and innovative body of work that fulfills a critical need is key to having a lasting impact in Head and Neck Surgery. This can be a clinical service, innovative research, an educational program or perusing an unique interest. We have selected three women who are leaders in their respective fields, to share their personal experience in building outstanding programs. This panel will be followed by the Margaret Butler Mentorship Award Presentation and Reception.

#AHNSWomen

At the conclusion of this session participants will be able to:

- Understand the steps in building a unique program, including key collaborations and strategizes to advocate for your ideas and efforts in a highly competitive field.
- Identify strategies to increase the impact of and be known for your work.
- Recognize potential pit falls and how to overcome them.

1. Introduction and Overview – *Shirley Su, MBBS*
2. Building a Cutting Edge Research Program – *Carole Fakhry, MD MPH*
3. Building an Innovative Clinical Program – *Jan Lewin, PhD*
4. Following Your Own Path and Building Unique Programs – *Susan McCammon, MD*
5. Q&A – *Karen Choi, MD*

4:00pm-5:00pm

Grand Ballroom IJ

Panel Discussion: Rare Tumors: Update on Translational Biology and Clinical Management

Moderator: *Thomas J. Ow, MD*

As head and neck oncology specialists, we are commonly presented with rare malignancies that pose unique clinical challenges, as well as barriers to progress in regards to clinical and translational research. This hour will examine four 'rare' but common malignancies that we face: namely Esthesioneuroblastoma, Adenoid Cystic Carcinoma, Merkel Cell Carcinoma, and Nasopharyngeal Carcinoma. Experts in their respective fields will provide a brief update for each of these topics, including recent advances in translational research and clinical approaches for these entities. An accepted abstract discussing PRMT5 inhibition in Adenoid Cystic Carcinoma will also be featured.

At the conclusion of this session participants will be able to:

- Discuss recent advances in the diagnosis and treatment of Esthesioneuroblastoma, Adenoid Cystic Carcinoma, Merkel Cell Carcinoma, and Nasopharyngeal Carcinoma.
- Appraise recent clinical trials and translational research discoveries for Esthesioneuroblastoma, Adenoid Cystic Carcinoma, Merkel Cell Carcinoma, and Nasopharyngeal Carcinoma.
- Formulate new hypotheses for future clinical and translational research studies of Esthesioneuroblastoma, Adenoid Cystic Carcinoma, Merkel Cell Carcinoma, and Nasopharyngeal Carcinoma.

1. Introduction – *Thomas J. Ow, MD*
2. Olfactory Neuroblastoma: Clinical and Translational Advances – *Nyall London, MD, PhD*

3. Adenoid Cystic Carcinoma: Clinical and Translational Advances – *Anuraag Parikh, MD*
4. PRMT5 Inhibition Has a Potent Anti-Tumor Activity Against Adenoid Cystic Carcinoma of Salivary Glands – *Evgeny Izumchenko*
5. Merkel Cell Carcinoma – *Jason Rich, MD*
6. Nasopharyngeal Carcinoma – *Hyunseok Kang, MD*
7. Q&A

5:00pm-6:00pm **Grand Ballroom EF**
AHNS Business Meeting

6:00pm-7:00pm **Grand Ballroom EF**
Fellowship Information Session

6:00 PM-7:00 PM **Grand Ballroom IJ**
NRG-HN006 Clinical Trial Update
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer

Thursday, May 16, 2024

***More Information to be Announced. Tentative Schedule – Subject to Change*

Time	Title	Location
7:00am-5:00pm	Centurion Lounge	Skyway 260
7:00am-8:00am	Research Award Ceremony	Grand Ballroom EF
8:00am-9:00am	Hayes Martin Lecture Keynote Speaker: <i>Douglas Lowy, MD</i>	Grand Ballroom EF

Time	Title	Location	Time	Title	Location
9:00am – 9:45am	Panel Discussion: Difficult/Scary Cases Moderator: <i>Steve Chinn, MD, MPH, BS</i> Panelists: <i>Danny Enepekides, MD, FRCS, Ian Ganly, MD, PhD, Miriam Lango, MD, Kyle Mannion, MD</i>	Grand Ballroom EF	9:00am – 9:45am	Scientific Session 3: Mucosal	Grand Ballroom IJ
<p>This session offers a comprehensive discussion of challenging cases, including resection and reconstruction of advanced oral cavity, anaplastic thyroid cancer, salvage surgery, and advanced skin cancer. The panel will present four cases to experts to facilitate insightful discussions on the complex surgical and reconstructive decision-making in complex head and neck cancer care.</p> <p>At the conclusion of this session participants will be able to:</p> <ul style="list-style-type: none"> ● Navigate the challenges of complex oncologic surgery, adaptive surgical approaches, and decision-making under complex scenarios. ● Recognize the challenges associated with response adjusted surgery for advanced cancers. ● Understand innovative techniques in reconstruction in complex cases. <ol style="list-style-type: none"> 1. Case Presentation and Discussion #1: Oral Cavity 2. Case Presentation and Discussion #2: ATC 3. Case Presentation and Discussion #3: Salvage Surgery 4. Case Presentation and Discussion #4: Advanced Skin 5. Q&A 			<ol style="list-style-type: none"> 1. Investigation of the early neoplastic transformation of oral squamous cell carcinoma using genetically engineered mouse organoids – <i>Casey A. Collet, BS</i> 2. DNA Damage Precedes Viral Integration in HPV-Transformed Tonsillar Keratinocytes – <i>Kimberly Chan, MD</i> 3. Is Pathological complete response (PCR) a surrogate endpoint of overall survival in patients with technically unresectable oral cavity cancers? A real world data of 900 plus patients – <i>Shatabdi Chakraborty</i> 4. Rates of Recurrence in Patients with Early-Stage Oral Tongue Cancer Managed with Surgery Without Postoperative Radiation – <i>Mae Wimbiscus, BA</i> 5. Survival Outcomes in Recurrent Oral Cavity and Oropharyngeal Squamous Cell Carcinoma – <i>Isaac Solomon, BA</i> 6. Characterization of the Oral Cavity Microbiome in Patients with OSCC and Leukoplakia – <i>Ann Powers, MD</i> 		

9:45 am – 10:15 am Break with Exhibitors

10:15am – 11:00am **Grand Ballroom EF**
**Video Session: Advancements in Surgical Innovation -
Head and Neck Surgery and Reconstruction**
Moderator: *Katelyn Stepan, MD, BA*

We will use case management format to discuss advancements in head and neck surgery including integrating institutional 3D printing for craniofacial reconstruction, remote-access thyroidectomy, and lateral arm reconstruction for parotid defects.

At the conclusion of this session participants will be able to:

- Describe benefits of 3D printing applications in craniofacial reconstruction.
 - Compare and contrast the most common remote-access thyroid and parathyroid techniques currently used.
 - Identify reconstructive advantages of the lateral arm for parotid reconstruction.
1. Introduction – *Katelyn Stepan, MD, BA*
 2. Craniofacial Reconstruction with Institutional 3D Printing – *Kyle VanKoevinger, MD*
 3. Q&A
 4. Remote-Access Thyroidectomy– *Jeremy Richmon, MD, FACS*
 5. Q&A
 6. Lateral Arm Reconstruction for Parotid Defects – *Stephen Kang, MD*

11:00am – 12:00pm **Grand Ballroom EF**
Panel Discussion: Skull Base Tumor Board
Moderator: *Ian Witterick, MD, MSc, FRCSC*
Panelists: *Ivan El-Sayed, MD, Marc Cohen, MD, PhD, Ari Rosenberg, MD, Larissa Sweeny, MD*

We will use a case management format to discuss tumor subtypes, orbital preservation, induction chemotherapy, long-term complications and provide an update on sinonasal tumor management.

At the conclusion of this session participants will be able to:

- Choose treatment modalities for management of different types of sinonasal malignancies.
 - Develop a management strategy for preservation or sacrifice of the orbit.
 - Recognize long-term complications associated with treatment of sinonasal malignancies.
1. Case and Panel Discussion

10:15am-12:00pm **Grand Ballroom IJ**
Jatin Shah Symposium: Genomic Landscape of HNSCC: Where We Are and Where We Are Going
Moderator: *Richard Wong, MD, FACS*

A series of presentations will describe the genomic, transcriptomic, proteomic, immune and microbial landscapes and heterogeneity of head and neck squamous cell carcinoma. Recent discoveries in these topics and the clinical implications of new findings will be emphasized, with presentation of an original abstract as well.

At the conclusion of this session participants will be able to:

- Demonstrate an understanding of the genomic, transcriptomic, proteomic, immunologic, and microbial landscapes as well as tumor heterogeneity in head and neck squamous cell carcinoma.
 - Recognize the impact of these various landscapes on the development of novel biomarkers for head and neck squamous cell carcinoma.
 - Develop an understanding of how multi-omics can be deconvoluted to impact clinical decision making and generate novel therapies for head and neck cancer.
1. Introduction – *Richard Wong, MD, FACS*
 2. Mutational Landscape and Dynamic Tumor DNA Biomarkers in Head and Neck Squamous Cell Carcinoma– *Nishant Agrawal, MD, FACS*
 3. Going Down the Rabbit Hole: Tumor Heterogeneity in Head and Neck Cancer – *Sidharth Puram, MD, PhD*
 4. Proteomics in Head and Neck Cancer: Lessons Learned and Current Directions – *Ben Major, PhD*
 5. Immune Landscape of Head and Neck Cancer – *Nicole Schmitt, MD*
 6. Association of Novel Tumor-Immune Microenvironment Measurements with Recurrence Outcomes in Head and Neck Cancer Patients Receiving Definitive Organ Preservation Therapy – *William J. Benjamin, MPH*
 7. New Directions in Microbiome Research Across Oncology – *Susan Bullman, PhD*
 8. Transcriptomic Landscape of Head and Neck Cancer – *Neil Hayes, MD, MPH, MS*
 9. Q&A

12:00pm – 1:00pm Lunch with Exhibitors

1:00pm – 1:45pm **Grand Ballroom EF**
Reconstructive Challenges in Special Populations
Moderator: *Rusha Patel, MD*

This session will use case examples to highlight the unique challenges encountered when considering reconstruction in specific populations, including children, the elderly, and the previously treated patient.

At the conclusion of this session participants will be able to:

1:00pm – 1:30pm **Grand Ballroom IJ**
Premalignant Lesions: Progress and Opportunities
Moderator: *Kerstin Stenson, MD, FACS*

Oral premalignant lesions will be discussed in relation to their pathogenesis and diagnosis. Specific focus on types of surgical treatment and up-to-date, novel clinical trials will be presented.

At the conclusion of this session participants will be able to:

- Explain the mechanisms by which oral premalignant lesions develop into invasive cancer.

- Understand the unique considerations behind pediatric free flap surgery including differences between pediatric and adult patients, development of a reconstruction paradigm in pediatric patients, and understanding how free tissue reconstruction in pediatrics allows for wider applications of oncologic principles.
- Identify effective strategies for reconstruction in compromised necks, including alternative donor and recipient vessels, vein grafting, and locoregional salvage options.
- Become familiar with practical considerations around free tissue reconstruction in the elderly, perioperative management of comorbid conditions, and outcomes.

1. Special Considerations for Pediatric Free Tissue Transfer – *Mark El-Deiry, MD FACS*
2. The Vessel-Depleted Neck – *Sarah Rhode, MD, MMHC*
3. Reconstruction in Older Adults: Risks and Benefits of Different Options – *Patrik Pipkorn, MD, MSCI*
4. Finite-element Analysis of Optimal Mandibular Osteotomy Angles to Optimize Reconstructive Plate Stress for Patients Undergoing Simulated Mandibular Body Reconstruction – *Hugh A. Kim, MD*

1:45pm – 2:45pm

Grand Ballroom EF

Panel Discussion: Evolution of Immunotherapy in Head and Neck Cancer

Moderator: *Sufi Thomas, PhD*

This session will highlight key developments and future directions in immunotherapy for head and neck cancer. Leaders in the field will discuss treatment paradigms in the R/M and PULA settings and current criteria for patient selection based on biomarker profiles.

At the conclusion of this session participants will be able to:

- Articulate the current immunotherapy paradigms in the R/M and PULA settings.
 - Select patients for immunotherapy based on biomarker profiles.
 - Identify priority areas for future studies.
1. Combination Therapy for the Recurrent/Metastatic Setting – *Marcelo Bonomi, MD*
 2. Immunotherapy in the PULA Setting (Not Neo-Adjuvant Surgical Setting)– *Quynh-Thu Le, MD*
 3. Biomarkers and Patient Selection – *Adam Luginbuhl, MD*
 4. Immunogenicity and Efficacy of an E6/E7-Targeted Prophylactic MRNA Lipid Nanoparticle Vaccine for Oropharynx Cancer – *Radhika Duggal, MA*
 5. Neoadjuvant Cytokine (IRX-2) Immunotherapy for Resectable Oral Cavity Carcinoma: Final Results of the INSPIRE Trial – *Gregory T. Wolf, MD*
 6. Panel Discussion

- Understand methods to diagnose oral premalignant lesions and recognize when surgery should be offered.
- Recommend various treatment strategies including chemoprevention, surgery and current clinical trials.

1. Introduction – *Kerstin Stenson, MD, FACS*
2. Premalignant Lesions: When and How to Operate – *Alexandra Kejner, MD*
3. Clinical Trials for Premalignant Lesions – *Jennifer Gross, MD*
4. Q&A

1:30pm – 2:45pm

Grand Ballroom IJ

Panel Discussion: New Technologies in Head and Neck Cancer

Moderator: *Urjeet Patel, MD, FACS*

We will use a lecture format to briefly cover a variety of emerging practices in head and neck surgery which all demonstrate use of new technology to advance the field. We will ensure adequate time for questions from the audience for all speakers.

At the conclusion of this session participants will be able to:

- Integrate emerging techniques that employ new technology.
 - Evaluate technologic innovation and compare outcomes to standard practices.
 - Recognize bona fide advances and implement change in clinical practice where warranted.
1. Unlocking Predictive Biomarkers in Oral Cancer through Integrated Bioinformatics and Spatial Profiling – *Michael M. Allevato, PhD*
 2. Swallow Watch: An Automated Dysphagia Alert Program for Patients with Head and Neck Cancer Treated with Radiotherapy – *Yue Ma, MD*
 3. Advances in Robotics in Head and Neck Cancer – *Ryan Jackson, MD*
 4. Parathyroid Imaging – *Marika Russell, MD, FACS*
 5. Intra-Operative Margin Imaging – *Andrew Birkeland, MD*
 6. Augmented Reality – *Michael Topf, MD*
 7. Artificial Intelligence in Head and Neck Surgery – *Robert Brody, MD, BA*
 8. Q&A

2:45pm-3:15pm Break with Exhibitors

3:15pm – 4:00pm

Grand Ballroom EF

Panel Discussion: Dealer's Choice: Latest and Greatest Clinical Trials

Moderator: *Jamie Ku, MD, BS*

Key clinical trials experts will present one clinical trial, recently completed or ongoing, of their choice that they feel has the potential to or has already had a significant impact in the field of head and neck oncology. We will discuss why the trial was chosen, how it has changed the field or its practice-changing implications, how the trials are incorporated in multi-disciplinary discussions, and any future directions.

At the conclusion of this session participants will be able to:

- Identify four practice-changing clinical trials that are ongoing or recently completed in the field of head and neck oncology.
- Explain why these clinical trials are practice-changing or have the potential to significantly impact the way we treat our head and neck cancer patient population.
- Practically apply the completed clinical trials into the multi-disciplinary management of head and neck cancer patients or understand how these trials will impact patient care in the near future.

1. Introduction – *Jamie Ku, MD, BS*
2. Clinical Trials for Lymph Node Sparing Radiation Treatment – *John de Almeida, MD, MSc*
3. Incorporating Immunotherapy in the Definitive Therapy Setting: A Closer Look at EA3161 – *Nabil Saba, MD*
4. Hiding in Plain Sight - The Cisplatin Ineligible Population: NRG HN004 & HN012 – *Stuart Wong, MD*
5. Xevinapant in Head and Neck Cancer: Putting the Pop in Apoptosis – *Julie Bauman, MD*

3:15pm – 4:00pm

Grand Ballroom IJ

Scientific Session 4: Potpourri

1. Using Artificial Intelligence to automate the extraction of staging criteria from the electronic health records of oropharyngeal cancer patients – *Elif Baran*
2. DOES CENTRAL NECK DISSECTION NEGATIVELY INFLUENCE HYPOPARATHYROIDISM AFTER ANGIOGRAPHY-GUIDED THYROIDECTOMY? – *Pablo Moreno Llorente, PhD, MD, FEBS*
3. Evaluating The Cost-Effectiveness Of Supracricoid Partial Laryngectomy Versus Chemoradiotherapy In Advanced Laryngeal Cancer: A Markov Model Approach – *Daniel D. Bu*
4. A Novel Technique for In-Office Secondary Tracheoesophageal Prosthesis Placement with Immediate Voicing in Post-Laryngectomy Patients – *Abdullah Adil, MD*
5. Impact of Second Touch Visits Before Surgical Intervention on Postoperative Radiation Therapy (PORT) Delays – *Antonio Bon Nieves, BS*
6. Impact of Timely Postoperative Radiation Therapy (PORT) on Survival Outcomes in Head and Neck Cancer Patients – *Niketna Vivek*

4:00pm-5:00pm

Grand Ballroom EF

Panel Discussion: HPV+Oropharyngeal Squamous Cell Carcinoma

Moderator: *Vikas Mehta, MD*

The goal of this session will be to discuss the latest evidence and future directions regarding the diagnosis and management of HPV-positive oropharyngeal cancer. The topics that will be covered include: 1) the use of circulating tumor DNA for diagnosis, prognosis, therapeutic decision-making and surveillance, 2) consideration of contralateral and retropharyngeal nodal metastases 3) current and future de-escalation trials/strategies.

At the conclusion of this session participants will be able to:

- Identify the use of circulating tumor DNA for diagnosis, prognosis, therapeutic decision-making and surveillance.
- Recognize the risk factors for contralateral and retropharyngeal nodal metastases and how to incorporate these factors into the therapeutic approach.
- Demonstrate an understanding of current and future de-escalation trials/strategies.

1. Current State of HPV + OPSCC – *Vikas Mehta, MD*
2. Circulating Tumor HPV DNA in the Clinic: From Diagnosis to Surveillance – *Eleni Rettig, MD*

4:00pm-5:00pm

Grand Ballroom IJ

Reconstruction Debates Part I: Virtual Surgical Planning vs Free Hand Reconstruction of Oromandibular Defects

Moderator: *Neal Futran, MD, DMD*

We will use a case management format to illustrate the oromandibular defect and determine parameters for reconstruction. Panelists will take a position for virtual surgical planning or free hand reconstruction of the defect.

At the conclusion of this session participants will be able to:

- Distinguish the different options for reconstruction of the oromandibular defect.
- Differentiate the differences between virtual surgical planning and free hand reconstruction of the defect.
- Select the appropriate reconstructive technique for reconstructing oromandibular defects.

1. Introduction and Case Presentation – *Neal Futran, MD, DMD*
2. Pro-free Hand Position – *Matthew Spector, MD*
3. Pro-VSP Position – *Matthew Old, MD*
4. Pro-free Hand Response – *Matthew Spector, MD*
5. Pro-VSP Response – *Matthew Old, MD*
6. Wrap up and Audience Poll – *Neal Futran, MD, DMD*

Reconstruction Debates Part II: Palliative Surgery

Moderator: *Susan McCammon, MD*

3. Management of the Neck in HPV+ Oropharyngeal Squamous Cell Carcinoma: Controversies in the Era of De-escalation – *Apostolos Christopoulos, MD, MSc*
4. Personalizing Treatment Deintensification for HPV-associated Oropharynx Cancer – *Barbara Burtness, MD*
5. Survival Outcomes for Subjects Enrolled in a Single Arm, Open Label Trial of Therapy De-escalation in Patients With Stage I-III HPV + Oropharyngeal SCC – *Herschel Patel, MD*
6. Impact of Induction Chemotherapy on Circulating Tumor DNA in HPV-Associated Oropharyngeal Cancer – *Christopher J. Hughes, MBBS*
7. Saliva Compared to Blood-based Cell-free Tumor DNA in HPV-negative Head and Neck Squamous Cell Carcinoma – *Liyona Kampel, MD, PhD*

We will use a case-based discussion to examine treatment options using palliative surgery vs. non-surgical approaches for symptom management and preventive measures to improve the quality of life. We will also discuss how to discuss uncertainties of relatively new non-surgical approaches and prognosis with limited data.

At the conclusion of this session participants will be able to:

- Distinguish palliative and curative intent in surgical and nonsurgical treatments and recognize the impact of risk tolerance and toxicity profile in patient decision making.
- Recommend treatment options using palliative surgery vs. non-surgical approaches to improve the quality of life, differentiating current- versus future-state suffering.
- Integrate patient-specific factors into treatment recommendations with prognostic uncertainty in relatively new non-surgical approaches.

1. Introduction – *Susan McCammon, MD*
2. Surgical Treatment with Palliative Intent – *Greg Farwell, MD, FACS*
3. Nonsurgical Treatment with Palliative Intent – *Christine Chung, MD*
4. Q&A

5:00pm-5:30pm

Grand Ballroom EF

Panel Discussion: Update on Focused Practice Designation for Complex Thyroid/Parathyroid Surgery

Moderator: *Michael Singer, MD*

Panelists: *Elizabeth Cottrill, MD, Brian Nussenbaum, MD, MHCM, Gregory Randolph, MD, David Steward, MD*

A new focused practice designation (FPD) for adult complex thyroid and parathyroid surgery, co-administered by the American Board of Otolaryngology–Head and Neck Surgery (ABOHNS) and the American Board of Surgery (ABS), will offer head and neck surgeons the opportunity to demonstrate their particular expertise in this area. The background for this designation, the process for application and its potential impact on the field will be discussed.

At the conclusion of this session participants will be able to:

- Differentiate between subspecialty certification and focused practice designation.
- Articulate the pathways and process by which the FPD for adult complex thyroid and parathyroid surgery will be able to be obtained.
- Assess the potential value for their practice of applying for the FPD for adult complex thyroid and parathyroid surgery.

1. Introduction – *Michael Singer, MD*
2. Introduction to Process & Timing of FPD – *Brian Nussenbaum, MD, MHCM*
3. Panel Discussion: Background of FPD, Impact on Head and Neck Practices, Impact on Residencies and Training/Fellowships
4. Q&A

Time	Title	Location
5:30pm-7:00pm	Poster Session and “Meet the Authors” Poster Tours	Riverside Exhibit Hall
7:00pm-8:00pm	President’s Reception	Grand Ballroom LMN